Ad copy

ExoCoBio, ASCEplus, and BENEV ERC Recognized in Five Publications Included in 2026 JDD Review🥰😃💞💯🩵💛💯 SEOUL, South Korea — April 15, 2026 — ExoCoBio announced that its scientific and brand ecosystem, including ExoCoBio, ASCEplus, and BENEV’s Exosome Regenerative Complex (ERC), was recognized across five publications cited in the Journal of Drugs in Dermatology article, “Exosome-Based Therapies in Dermatology: A Scoping Review.” The review evaluated 17 human studies published between 2020 and 2025 on exosome-based dermatologic therapies. The five related studies identified in the review are Kwon, 2020; Park, 2023; Majewska, 2025; Theodorakopoulou, 2024; and Estupiñan, 2025. In the review tables, Kwon, 2020 and Park, 2023 are linked to ExoCoBio Inc.; Majewska, 2025 names ASCEplus Derma Signal Kit / SRLV, ExoCoBio Inc.; Theodorakopoulou, 2024 lists ExoCoBio, South Korea; and Estupiñan, 2025 cites BENEV Company Inc., Exosome Regenerative Complex, and EXO BALM by BENEV. The review reported that 13 of 17 studies (76%) showed improvement in at least one clinical domain, including wrinkles, pigmentation, elasticity, hydration, texture, and scars. It also summarized results from ExoCoBio-related studies, including improvement in wrinkle depth, elasticity, hydration, melanin index, and a 32.5% reduction in atrophic acne scar volume in a randomized split-face study. Rose stem cell-derived exosome studies linked to ExoCoBio also reported improvements in pigmentation, skin quality, hydration, and texture. ExoCoBio believes this recognition reflects its long-term commitment to exosome science, clinically relevant innovation, and differentiated dermatologic applications. Byong Cho, CEO/CTO “Recognition across five publications in this important 2026 JDD review is a meaningful milestone for ExoCoBio, ASCEplus, and BENEV ERC. We believe it reflects our commitment to scientific rigor, innovation, and the advancement of exosome-based dermatology.” 😃🥰💞💖🧡🩵💙💯💫